VCBeat Health
Contact Us
Home
China Healthcare Select
Insights
MNC China Lens
Vertical Industries
Services
Partnership Development
Market Entry Advisory
Ecosystem Engagement Advisory
About VCBeat
Why VCBeat
Log In
Home
Kezhou Pharmaceutical Files for BSE IPO: Can Its NRAS-Mutant Melanoma Drug Story Sustain Until Listing?
Kezhou Pharmaceutical Files for BSE IPO: Can Its NRAS-Mutant Melanoma Drug Story Sustain Until Listing?
May 28, 2026 17:13 CST Updated 18:56
Share:
